Market Cap
$2.9B
TMDX
TransMedics Group, Inc.
$77.49 ▼ -1.46%
Prev close $78.64Market cap$2.9B
ConsensusBuy
12-mo target$97.30 (+25.6%)
▲ Bullish
Analyst conviction 7/10
Insider Selling Cluster (3 insiders)High Impact Filing (8/10)24 New Institutional Positions26 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on TMDX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Buy (68%)
Inst. Holders
50 funds
Inst. Value
$2.1B
Inst. Activity
24 buys / 26 sells
Insider Activity
$109.1K buy / $1.5M sell
Insider Net $
-$1.4M
Social Sentiment
64° Warm
SEC Reports
6
Price chart 30d -8.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 11, 2026 Insider
Weill David bought 1,336 shares
Director @ $81.63 ($109.1K)
Sep 11, 2026 short_volume
Short Volume: TMDX — 61.5% short (0.4M / 0.6M)
Short: 352,817 | Exempt: 800 | TRF Vol: 574,134 | Short Ratio: 61.5% | Off-exchange volume (dark poo
Aug 17, 2026 Insider
TOBIN JAMES R gifted 18,000 shares
Director
Jul 10, 2026 Insider
Corcoran Nicholas was granted 11,727 shares
See remarks
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — TRIM
559,771 shares ($37.2M)
Jun 30, 2026 Inst.
Jun 12, 2026 SEC CITADEL ADVISORS LLC — DOUBLED
558,824 shares ($37.1M)
TransMedics attracted heavy net institutional accumulation in Q3 2024, with 25 buyers adding $121.7M in new exposure aga
INST-CLUSTER — Impact 6/10
A bullish institutional cluster formed in TMDX during Q3 2025, with 5 buyers adding $66.4M in net new holdings versus 2
INST-CLUSTER — Impact 5/10
Analyst ratings buy % -15.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
68% rate it Buy or better · 19 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | TD Cowen | REITERATE | Buy | 56% |
| Aug 5, 2026 | UBS | MAINTAIN | Neutral | 55% |
| Aug 5, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
| Aug 3, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 28, 2026 | UBS | INITIATE | Neutral | 55% |
| Jul 6, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Jul 1, 2026 | TD Cowen | REITERATE | Buy | 56% |
| Jun 30, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jun 18, 2026 | Stifel | MAINTAIN | Hold | 54% |
| May 26, 2026 | Stifel | MAINTAIN | Hold | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 5 | 8 | 6 | 0 | 0 | 68% | |
| Aug 1, 2026 | 5 | 8 | 6 | 0 | 0 | 68% | |
| Jul 1, 2026 | 5 | 9 | 5 | 0 | 0 | 74% | |
| Jun 1, 2026 | 5 | 9 | 5 | 0 | 0 | 74% | |
| May 1, 2026 | 7 | 9 | 4 | 0 | 0 | 80% | |
| Apr 1, 2026 | 7 | 9 | 4 | 0 | 0 | 80% | |
| Mar 1, 2026 | 7 | 9 | 4 | 0 | 0 | 80% | |
| Feb 1, 2026 | 7 | 9 | 4 | 0 | 0 | 80% |
Price targets
Where 10 covering analysts think TMDX trades over the next 12 months.
$97.30 +25.6% upside Strong Buy
Current$77.49 Low$65.00 Median$97.50 High$125.00 10 analysts
$65.00$125.00
Analyst rating Buy· 1.8/5 as of Oct 2, 2026
Social media sentiment mood -16.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
64°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 3 neutral · avg impact 4.8/10.
BULLISHINST-CLUSTER6/10
TransMedics attracted heavy net institutional accumulation in Q3 2024, with 25 buyers adding $121.7M
Jun 12, 2026
BULLISHINST-CLUSTER5/10
A bullish institutional cluster formed in TMDX during Q3 2025, with 5 buyers adding $66.4M in net ne
Jun 11, 2026
NEUTRALDEFA14A3/10
TransMedics Group, Inc. is holding its 2026 Annual Meeting, where shareholders will vote on director
Apr 10, 2026
NEUTRALCLUSTER3/10
Two TransMedics insiders conducted open-market share sales within the past week, totaling approximat
Mar 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 11, 2026
short_volume
Short Volume: TMDX — 61.5% short (0.4M / 0.6M)
Short: 352,817 | Exempt: 800 | TRF Vol: 574,134 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
Sep 11, 2026
ftd
FTD: TMDX — 31,021 shares ($2.6M) failed to deliver
Settlement: 20260911, Price: $85.04, FTD Value: $2,638,025.84, TRANSMEDICS GROUP INC COM
Sep 1, 2026
other
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary du
Aug 31, 2026
other
TransMedics to Present at Upcoming September Investor Conferences
ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transformin
Aug 25, 2026
ftd
FTD: TMDX — 98,071 shares ($9.2M) failed to deliver
Settlement: 20260825, Price: $93.60, FTD Value: $9,179,445.6, TRANSMEDICS GROUP INC COM
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.29 | $0.15–$0.40 | -56.5% | -3.8% | 0↑ 6↓ | $0.2B | 8 |
| Next Q | $0.50 | $0.31–$0.57 | -5.5% | -5.9% | 1↑ 5↓ | $0.2B | 8 |
| Current FY | $1.52 | $1.17–$1.63 | -42.1% | -2.5% | 0↑ 7↓ | $0.7B | 9 |
| Next FY | $2.28 | $1.74–$3.04 | 50.3% | -0.9% | 0↑ 7↓ | $0.9B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.287 | — |
| 7d ago | $0.287 | — |
| 30d ago | $0.299 | -0.011 |
| 60d ago | $0.417 | -0.130 |
| 90d ago | $0.427 | -0.140 |
Institutional ownership
Which big funds own TMDX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $2.1B total value (31,096,738 shares) as of 2026-Q2. Top holders: BlackRock,, FMR, VANGUARD. Net selling activity: 26 institutions trimmed/exited vs 24 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 5,596,549 | $371.7M | 18.0% | — |
| FMR LLC | 5,133,328 | $341.0M | 16.5% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,933,989 | $128.5M | 6.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,497,600 | $99.5M | 4.8% | — |
| STATE STREET CORP | 1,420,421 | $94.3M | 4.6% | — |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 910,495 | $60.5M | 2.9% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 894,913 | $59.5M | 2.9% | — |
| Hood River Capital Management LLC | 751,133 | $49.9M | 2.4% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 665,200 | $44.2M | 2.1% | ADD +90.8% |
| DIMENSIONAL FUND ADVISORS LP | 610,107 | $40.5M | 2.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | TRIM | 866,282 | 559,771 | -35.4% | $37.2M |
| CITADEL ADVISORS LLC | DOUBLED | 61,601 | 558,824 | +807.2% | $37.1M |
| MORGAN STANLEY | TRIM | 694,150 | 405,112 | -41.6% | $26.9M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | 939,523 | 398,250 | -57.6% | $26.5M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 133,875 | 255,398 | +90.8% | $17.0M |
| Tidal Investments LLC | NEW | — | 251,196 | — | $16.7M |
| CONGRESS ASSET MANAGEMENT CO | NEW | — | 227,834 | — | $15.1M |
| JPMORGAN CHASE & CO | TRIM | 308,341 | 192,269 | -37.6% | $13.0M |
| Point72 Asset Management, L.P. | NEW | — | 192,594 | — | $12.8M |
| FRONTIER CAPITAL MANAGEMENT CO LLC | TRIM | 320,471 | 150,162 | -53.1% | $10.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 25 transactions. Net -$1.4M — $109.1K bought, $1.5M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Weill David | Director | BUY | 1,336 | $81.63 | $109.1K |
| Aug 17, 2026 | TOBIN JAMES R | Director | GIFT | 18,000 | — | — |
| Jul 10, 2026 | Corcoran Nicholas | See remarks | AWARD | 11,727 | — | — |
| Jul 10, 2026 | Hernandez Gerardo | Chief Financial Officer | AWARD | 17,246 | — | — |
| Jul 10, 2026 | Corcoran Nicholas | See remarks | AWARD | 17,784 | — | — |
| Jul 10, 2026 | Hernandez Gerardo | Chief Financial Officer | AWARD | 26,153 | — | — |
| Jul 10, 2026 | Hassanein Waleed H | President & CEO | AWARD | 49,669 | — | — |
| Jul 10, 2026 | Hassanein Waleed H | President & CEO | AWARD | 112,984 | — | — |
| Jun 15, 2026 | Gunderson Thomas J. | Director | SELL | 9,624 | $75.06 | $722.4K |
| Jun 15, 2026 | Gunderson Thomas J. | Director | EXERCISE | 19,285 | $2.21 | $42.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TMDX.
Shares short
7,977,125
Settlement Sep 15, 2026
Change vs prior
-1.3%
Semi-monthly cycle
Days to cover
10.7
At avg daily volume
Of shares outstanding
≈23.0%
Estimate — not % of float
All TMDX filing & press-release reports (6)
- INST-CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- DEFA14A reportApr 10, 2026
- CLUSTER reportMar 6, 2026
- 8-K reportFeb 27, 2026
- 8-K reportFeb 24, 2026